SCHEMBL24322186

SCHEMBL24322186

CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4sc5c(nc(C)n5C(C)C)c4C)n3)nn1)C2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 20/20 0.68
CDK4 P11802 12/20 0.68
CDK6 Q00534 11/20 0.67
CIT O14578 1/20 0.46
GAK O14976 1/20 0.46
DYRK3 O43781 1/20 0.46
CCNT1 O60563 1/20 0.46
STK16 O75716 1/20 0.46
CCNK O75909 1/20 0.46
STK10 O94804 1/20 0.46
PRKD3 O94806 1/20 0.46
ABCB11 O95342 1/20 0.46
MAP4K4 O95819 1/20 0.46
CCNE2 O96020 1/20 0.46
EGFR P00533 1/20 0.46
NTRK1 P04629 1/20 0.46
PRKCB P05771 1/20 0.46
CDK1 P06493 1/20 0.46
PIM1 P11309 1/20 0.46
CCNB1 P14635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515159 1.00 CCND1 (0.68) CCND1CDK4CDK6CITGAK
SCHEMBL24322185 0.90 CCND1 (0.75) CCND1CDK4CDK6CITGAK
SCHEMBL24322348 0.90 CCND1 (0.84) CCND1CDK4CDK6
SCHEMBL30541489 0.84 CCND1 (0.61) CCND1CDK4CDK6
SCHEMBL29514918 0.82 CCND1 (0.84) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL24322347 0.82 CCND1 (0.84) CCND1CDK4CDK6CCNA2CDK2
SCHEMBL29515047 0.81 CCND1 (1.00) CCND1CDK4CDK6
SCHEMBL24323617 0.81 CCND1 (1.00) CCND1CDK4CDK6
SCHEMBL25284830 0.80 CCND1 (1.00) CCND1CDK4CDK6CITGAK
SCHEMBL29515035 0.80 CCND1 (1.00) CCND1CDK4CDK6CITGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 US disclosed
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 US disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 US disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 US disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CCND1 46/4885CDK4 12/4885CDK6 1/4885
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 CCND1 46/4885CDK4 12/4885CDK6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.